BIODELIVERY SCIENCES INTERNATIONAL INC 4

Accession 0000899243-16-029936

CIK 0001103021operating

View on SEC.gov Company Profile

Filed

Sep 22, 8:00 PM ET

Accepted

Sep 23, 6:30 PM ET

Size

26.7 KB

Accession

0000899243-16-029936

Insider Transaction Report

Form 4

Period: 2016-09-21

BIODELIVERY SCIENCES INTERNATIONAL INCBDSI

Vasisht Niraj

Chief Technology Officer

Transactions

Exercise/Conversion
Restricted Stock Units
2016-09-21−66,667→ 133,333 total
Exercise: $0.00From: 2016-02-23Exp: 2018-02-23→ Common Stock (66,667 underlying)
Exercise/Conversion
Common Stock
2016-09-21+24,980→ 142,394 total
Sale
Common Stock
2016-09-23$2.68/sh−7,000$18,760→ 162,061 total
Award
Common Stock
2016-09-21+4,661→ 73,081 total
Exercise/Conversion
Restricted Stock Units
2016-09-21−16,667→ 16,666 total
Exercise: $0.00From: 2016-01-30Exp: 2017-01-30→ Common Stock (16,667 underlying)
Exercise/Conversion
Restricted Stock Units
2016-09-21−27,666→ 0 total
Exercise: $0.00From: 2016-02-20Exp: 2016-09-21→ Common Stock (27,666 underlying)
Exercise/Conversion
Common Stock
2016-09-21+16,667→ 117,414 total
Exercise/Conversion
Common Stock
2016-09-21+66,667→ 209,061 total
Exercise/Conversion
Common Stock
2016-09-21+27,666→ 100,747 total
Sale
Common Stock
2016-09-21$2.39/sh−40,000$95,600→ 169,061 total
Exercise/Conversion
Restricted Stock Units
2016-09-21−24,980→ 24,980 total
Exercise: $0.00From: 2016-02-22Exp: 2017-02-22→ Common Stock (24,980 underlying)

Footnotes (9)

[F1]The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016.
[F2]The shares of common stock were acquired by the Reporting Person as a result of the vesting of 27,666 RSUs granted to the Reporting Person on February 20, 2013 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on September 21, 2016.
[F3]The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on January 30, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remaining half of the RSUs under this grant will vest on January 30, 2017.
[F4]The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on February 22, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remaining half of the RSUs under this grant will vest on February 22, 2017.
[F5]The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remainder of the RSUs under this grant will vest in equal portions on each of (i) February 23, 2017 and (ii) February 23, 2018.
[F6]The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs.
[F7]On September 21, 2016, the Reporting Person sold an aggregate of 40,000 shares of the Issuer's Common Stock at a weighted average price of $2.39 per share. The highest sale price for the Common Stock was $2.45 per share and the lowest sale price was $2.35 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F8]The shares of common stock were sold upon expiration of a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's additional tax liability upon the vesting of RSUs.
[F9]On September 23, 2016, the Reporting Person sold an aggregate of 7,000 shares of the Issuer's Common Stock at a weighted average price of $2.68 per share. The highest sale price for the Common Stock was $2.81 per share and the lowest sale price was $2.58 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

BIODELIVERY SCIENCES INTERNATIONAL INC

CIK 0001103021

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0001103021

Filing Metadata

Form type: 4
Filed: Sep 22, 8:00 PM ET
Accepted: Sep 23, 6:30 PM ET
Size: 26.7 KB

View on SEC.gov